載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.105
−US$0.045 · -3.91%
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
前收盤價
US$1.105
−US$0.045 · -3.91%
盤後
US$1.1004
−US$0.0046 · -0.42%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
日內區間
目前US$1.105
52週區間
目前US$1.105
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.53萬 USD | 21.78萬 USD | 83.2萬 USD | 1026.23萬 USD | 177.48萬 USD |
| 毛利 | 6.53萬 USD | 21.78萬 USD | 83.2萬 USD | 1026.23萬 USD | 177.48萬 USD |
| 研究與開發 | 5420.69萬 USD | 7562.03萬 USD | 8667.66萬 USD | 1.88億 USD | 2.49億 USD |
| 銷售、一般及管理費用 | 3268.06萬 USD | 3699.63萬 USD | 4758.21萬 USD | 9018.53萬 USD | 5375.24萬 USD |
| 營業費用 | 8688.74萬 USD | 1.13億 USD | 1.45億 USD | 2.78億 USD | 3.03億 USD |
| 利息收入 | 242.02萬 USD | 476.7萬 USD | 813.33萬 USD | 478.2萬 USD | 336.31萬 USD |
| 利息支出 | — | 17.78萬 USD | 122.28萬 USD | 125.4萬 USD | 193.64萬 USD |
| 折舊和攤銷 | 298.88萬 USD | 313萬 USD | 350.35萬 USD | 549.6萬 USD | 473.08萬 USD |
| 營業利益 | −8682.21萬 USD | −1.12億 USD | −1.44億 USD | −2.68億 USD | −3.01億 USD |
| 淨利 | −8494.59萬 USD | −1.07億 USD | −1.35億 USD | −2.8億 USD | −3.04億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$2.75
上漲空間 148.87%| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2017年9月28日 | US$0.0057Monthly | 2017年9月29日 | 2017年10月16日 |
股息 | 2017年8月29日 | US$0.0057Monthly | 2017年8月31日 | 2017年9月15日 |
股息 | 2017年7月27日 | US$0.0057Monthly | 2017年7月31日 | 2017年8月15日 |
股息 | 2017年6月28日 | US$0.0057Monthly | 2017年6月30日 | 2017年7月17日 |
除息 2017年9月28日
US$0.0057
Monthly
2017年9月29日登記 · 支付日 2017年10月16日
除息 2017年8月29日
US$0.0057
Monthly
2017年8月31日登記 · 支付日 2017年9月15日
除息 2017年7月27日
US$0.0057
Monthly
2017年7月31日登記 · 支付日 2017年8月15日
除息 2017年6月28日
US$0.0057
Monthly
2017年6月30日登記 · 支付日 2017年7月17日
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Invesco NASDAQ Future Gen 200 ETFQQQSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
